Targeted Next-Generation Sequencing in Blast Phase Myeloproliferative Neoplasms

A study out of Mayo Clinic using targeted next-generation sequencing analyzed the DNA of 248 patients with blast phase MPNs and found that RUNX1 mutations may predict inferior survival in these patients independent of specific treatment strategies.

 Blood Advances

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.